Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brodalumab switch study in psoriasis after inadequate TNF-alpha inhibitor response
2018-001021-10Phase 4Completed
- Sponsor
- Sahlgrenska University Hospital
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of brodalumab in plaque psoriasis (2 arms), sponsored by Sahlgrenska University Hospital. Primary endpoint: Proportion of subjects achieving PASI <3 after 12 weeks of treatment. Started May 2018; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2018-001021-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001021-10.